Direkt zum Inhalt
Merck
  • A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

PloS one (2015-03-31)
Benjamin D Brooks, Kristofer D Sinclair, David W Grainger, Amanda E Brooks
ZUSAMMENFASSUNG

Nearly 1.3 million total joint replacement procedures are performed in the United States annually, with numbers projected to rise exponentially in the coming decades. Although finite infection rates for these procedures remain consistently low, device-related infections represent a significant cause of implant failure, requiring secondary or revision procedures. Revision procedures manifest several-fold higher infection recurrence rates. Importantly, many revision surgeries, infected or not, require bone void fillers to support the host bone and provide a sufficient tissue bed for new hardware placement. Antibiotic-eluting bone void fillers (ABVF), providing both osteoconductive and antimicrobial properties, represent one approach for reducing rates of orthopedic device-related infections. Using a solvent-free, molten-cast process, a polymer-controlled antibiotic-eluting calcium carbonate hydroxyapatite (HAP) ceramic composite BVF (ABVF) was fabricated, characterized, and evaluated in vivo using a bacterial challenge in a rabbit radial defect window model. ABVF loaded with tobramycin eliminated the infectious burden in rabbits challenged with a clinically relevant strain of Staphylococcus aureus (inoculum as high as 10⁷ CFU). Histological, microbiological, and radiographic methods were used to detail the effects of ABVF on microbial challenge to host bone after 8 weeks in vivo. In contrast to the HAP/BVF controls, which provided no antibiotic protection and required euthanasia 3 weeks post-operatively, tobramycin-releasing ABVF animals showed no signs of infection (clinical, microbiological, or radiographic) when euthanized at the 8-week study endpoint. ABVF sites did exhibit fibrous encapsulation around the implant at 8 weeks. Local antibiotic release from ABVF to orthopedic sites requiring bone void fillers eliminated the periprosthetic bacterial challenge in this 8-week in vivo study, confirming previous in vitro results.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, 36.5-38% in H2O
SAFC
Formaldehyd -Lösung, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Methylmethacrylat, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
L-Lysin -monohydrochlorid, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Formaldehyd -Lösung, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Supelco
Formaldehyd -Lösung, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
Methylmethacrylat, 99%, stabilized
Sigma-Aldrich
Polyethylenglykol-Bisphenol A Epichlorhydrin-Copolymer, mol wt 15,000-20,000 Da
Sigma-Aldrich
Formaldehyd -Lösung, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
L-Lysin -monohydrochlorid, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Formaldehyd -Lösung, tested according to Ph. Eur.
Sigma-Aldrich
2-Methoxy-2-phenylacetophenon, 96%
Sigma-Aldrich
Phthalsäure-monobutylester, 97.0-103.0% (T)
Sigma-Aldrich
2-Methoxy-2-phenylacetophenon, 99%
Sigma-Aldrich
Formaldehyd-12C -Lösung, 20% in H2O, 99.9 atom % 12C
Supelco
L-Lysin -monohydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysin -monohydrochlorid, BioUltra, ≥99.5% (AT)
Lysin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Methylmethacrylat, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysin -monohydrochlorid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Lysin-hydrochlorid -Lösung, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
Phthalsäure-monobutylester, analytical standard